Skip to main content

Diabetes Drug News

Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.

Metformin     Insulin     SGLT-2     GLP-1     DPP-4     Combo drugs     Sulfonylureas     TZDs

How a new trial is testing a novel pill for blood glucose management – currently enrolling!
Twitter summary: FDA approves Novo Nordisk’s chronic weight management drug Saxenda, another option to help treat #obesity On December 23, the FDA approved Novo Nordisk’...
Complete with a savings card, a patient coaching program, and more!
How fast are insulin prices actually rising? Why might this be happening, and what is the impact on patients with varying levels of health care coverage?
Our deep dive on a new therapy now available in Europe – the benefits, risks, and when it might come to the US.
A clinical trial takes a new approach to type 1 prevention research.
The symptoms, who is at risk, and what every patient on SGLT-2 inhibitors can do right now.
What happens when these two unique drugs are taken together?
How a single change at the FDA could lead to major improvements for patients and the healthcare system.
Lilly announced that the FDA has approved its Humalog 200 units/mL KwikPen (insulin lispro) for type 1 and type 2 diabetes, making it the first concentrated mealtime...
Sanofi and MannKind announce Afrezza's official US launch.
How these two FDA-submitted drugs could address this major healthcare need.
Kicking off this weekend, what are we most excited about for this year’s ADA?
How a major research study is challenging an outdated FDA restriction.
What this dramatic movement in obesity therapy means for patients in Europe.
By Kelly Close Twitter Summary: @kellyclose speaks to @US_FDA in favor of PCSK9 inhibitor drug Praluent – need to bring more options to #PWD to fight against CV disease...
How this “disease interception” strategy could transform our knowledge of type 1 diabetes.
Dr. Doug Melton and colleagues at the Harvard Stem Cell Institute recently announced new partnerships with Novartis and AstraZeneca to advance stem cell research for...
One of the biggest drug highlights at the 2015 ADA Scientific Sessions was a compelling presentation by diaTribe scientific Advisory Board member Dr. John Buse on brand...
First-ever SGLT-2/DPP-4 inhibitor drug, will this combination cut costs for patients?

Pages